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                 PENILAIAN TERHADAP PENGGUNAAN GABUNGAN  
METFORMIN-LOVASTATIN DALAM RAWATAN 
PESAKIT DIABETES JENIS 2 DENGAN DISLIPIDEMIA 
DI HOSPITAL PULAU PINANG 
 
 
              ABSTRAK 
 
Diabetes jenis 2 dapat dicirikan melalui kehadiran rintangan insulin yang 
sering wujud bersama dengan pelbagai faktor risiko kardiovaskular.  
Dislipidemia merupakan faktor risiko yang telah dikenalpasti dan boleh 
diubah suai. Ianya perlu dirawat segera secara agresif untuk mengelak 
daripada berlakunya prognosis penyakit kardiovaskular. Kajian ini ber 
matlamat untuk menilai hasilan klinikal di sebalik penggunaan metformin 
dan lovastatin dalam rawatan pesakit diabetes  jenis 2 dengan  dislipidemia. 
Di samping itu, suatu penilaian tentang perbezaan dalam respons terapeutik  
turut dilakukan berdasarkan faktor bangsa dan gender.  Suatu pemerhatian 
retrospektif dijalankan di klinik pesakit luar, Hospital Pulau Pinang, 
Malaysia. Data seperti demografi, profil perubatan, dan maklumat daripada 
ujian makmal telah dikumpulkan dan dianalisis dengan menggunakan 
program SPSS (Pakej Statistik daripada Sains Sosial) versi 15. Daripada 873 
rekod perubatan yang terkumpul, hanya 501 pesakit memenuhi kriteria 
kajian ini. Responden wanita terdiri dari 55.9%, sementara 44.1% adalah 
responden lelaki. Berdasarkan taburan bangsa, responden Cina adalah 
41.7%, diikuti 34.3% Melayu dan 24% India. Secara signifikan, responden Cina 
menunjukkan peratusan tahap HDL terkawal tertinggi iaitu 97.5%. Berbeza 
dengan lelaki, secara signifikannya, responden wanita menunjukkan min TC 
(Total cholesterol) dan nilai HDL (High density lipoprotein) tertinggi (5.40 
xvii 
 
± 1.09 mmol/l dan 1.32 ± 0.29 mmol/l masing-masing). Profil lipid secara 
signifikannya dikurangkan ke tahap normal dalam tempoh kajian. Begitu 
juga dengan min FPG (Fasting plasma glucose) yang semakin berkurangan. 
Namun demikian, nilai-nilai tersebut didapati melebihi matlamat rawatan 
(8.22 ± 2.33 mmol/l). Kajian ini juga menunjukkan bahawa 93.5% daripada 
pesakit dengan LDL terkawal adalah secara signifikannya berada dalam 
rawatan dos terapeutik metformin. Sebaliknya, secara signifikan, status 
lipidemia terkawal didapati lebih tinggi (86.6%) dalam kalangan pesakit 
yang mendapat rawatan monoterapi lovastatin. Pesakit dengan tahap FPG 
yang tidak terkawal mempunyai korelasi dengan tahap TG (Triglyceride) 
tidak terkawal (81.7%). Berdasarkan gaya hidup pesakit, didapati diet yang 
tidak terkawal dihubungkaitkan dengan FPG yang tidak terkawal. Didapati, 
78.7% daripada pesakit yang mengamalkan senaman mempunyai lipidemia 
yang terkawal. Walau bagaimanapun, 90.8% daripada pesakit yang 
mempunyai gaya hidup yang tidak terkawal, mengalami komplikasi. 
Sebagai kesimpulan, metformin dan lovastatin, sama ada sebagai 
monoterapi atau dalam gabungan dengan agen antidiabetes atau 
antihiperlipidemik lain adalah efektif dalam mengurangkan peningkatan 
glukosa dan profil lipid. Walau bagaimanapun, min FPG masih 
menunjukkan kawalan yang lemah. Kedua-dua drug menunjukkan toleransi 
yang baik dengan kesan mudarat yang minor.   Kajian ini mencadangkan 
agar kawalan glukosa dan lipid yang ketat berserta dengan gaya hidup yang 
baik adalah perlu untuk mencapai hasil yang baik.    
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Kata kunci:  diabetes jenis 2, dislipidemia diabetes, metformin, lovastatin,       
kawalan glisemik, kepatuhan kepada ADA dan garis panduan diabetes 
Malaysia. 
EVALUATION OF COMBINED METFORMIN-LOVASTATIN 
THERAPY IN THE TREATMENT OF DIABETIC TYPE 2 
PATIENTS WITH DYSLIPIDEMIA IN HOSPITAL PULAU 
PINANG 
 
 
            ABSTRACT 
 
 Diabetes type 2 is characterized by the presence of insulin resistance which 
frequently co-exists with multiple cardiovascular risk factors. Dyslipidemia 
is a well-recognized and modifiable risk factor that should be identified and 
treated aggressively to prevent the onset and prognosis of cardiovascular 
disease. This study aimed to assess the clinical outcomes behind the usage 
of metformin and lovastatin in the treatment of diabetes type 2 patients with 
dyslipidemia. Furthermore, an evaluation of difference in therapeutic 
response was done according to race and gender. A retrospective 
observational study was performed at the outpatient clinic of Hospital Pulau 
Pinang, Malaysia. Demographic, medication profile, and laboratory tests 
information were collected. Data were analyzed by using Statistical Package 
of Social Sciences (SPSS) program version 15. From 873 medical records, 
only 501 patients met the inclusion criteria of this study. Females constituted 
55.9%, while 44.1% were males. Racial distribution showed that Chinese 
were 41.7%, Malay 34.3% and Indians 24%. Significantly, Chinese showed 
the highest percentage (97.5%) of controlled HDL levels. Unlike males, 
females demonstrated the highest mean TC and HDL values (5.40 ± 1.09 
mmol/l and 1.32 ± 0.29 mmol/l respectively) significantly. Lipid profile has 
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been reduced significantly to the normal levels within the study period. 
Similarly, mean FPG has been decreased. However, those values were 
observed to be above treatment goals (8.22 ± 2.33 mmol/l). This study also 
revealed that 93.5% of patients with controlled LDL were on therapeutic 
doses of metformin significantly. Controlled dyslipidemia status was 
attained to be more (86.6%) among patients on lovastatin monotherapy 
significantly. Patients with uncontrolled FPG levels were correlated with the 
uncontrolled TG levels (81.7%). Based on patients’ lifestyle, it was 
observed that uncontrolled diet was associated significantly with the 
uncontrolled FPG. Noticeably, 78.7% of patients performed exercise had 
controlled dyslipidemia. However, 90.8% of patients with uncontrolled 
lifestyle suffered from complications. In conclusion, metformin and 
lovastatin either as monotherapy or in combination with other antidiabetic or 
antidyslipidemic agents were effective in reducing elevated glucose and 
lipid profile. However, mean FPG still indicating poor control. Both drugs 
were well tolerated with minor adverse effects reported. This study 
recommends strict glycemic and lipid control coupled with lifestyle 
modifications to achieve better outcomes.  
Keywords: diabetes type 2, diabetic dyslipidemia, metformin, lovastatin, 
glycemic control, Malaysian clinical practice guidelines. 
 
 1 
CHAPTER 1 
 
INTRODUCTION 
1.1 Background 
Diabetes mellitus is one of the most common, widely distributed metabolic disorders 
around the world (WHO, 1985). This disorder is characterised by hyperglycemia 
resulting from defects in insulin action or secretion or both (The Expert Committee 
on the Diagnosis and Classification of Diabetes Mellitus, 1997; ADA, 2004; Lin and 
Sun, 2009). Such defects may be accompanied by changes in fat, carbohydrate and 
protein metabolism (Levene, 2003).  
The term Diabetes mellitus is an ancient Greek and Roman term that means “passing 
through of sugar”. It refers to one of the diabetes major symptoms (excessive 
production of sweet and smelly urine or polyuria). This term is used also to describe 
other features of diabetes such as thirst (polydypsia) and weight loss despite 
increasing appetite, or polyphagia (Leahy, 2000). These clinical features were 
depicted by the ancient Egyptians 3000 years ago, and later in 1675, sweetness of 
patient blood and urine were noticed by the ancient Indians. Only in 1776 Dobson 
confirmed that the presence of excess sugar in the blood and urine was the cause of 
sweetness (Ahmed, 2002).  
Diabetes is a chronic non-curable complex disease that affects most body organs 
resulting in severe complications such as cardiovascular disease, peripheral vascular 
disease, stroke, renal failure, blindness, amputation and premature death (Engelgau 
and Geiss, 2000; Harvey et al., 2006).  
Diabetes mellitus is classified into two major types, which are, insulin-dependent 
diabetes mellitus (IDDM) or type 1 (known as juvenal-onset), and non-insulin 
 2 
dependent diabetes mellitus (NIDDM) or type 2 (known as adult-onset). Other 
classes include impaired glucose tolerance (IGT) and the gestational diabetes 
mellitus (WHO, 1999).  
Diabetes type 1 results from the autoimmune destruction of β-cells that are 
responsible for producing insulin in the pancreas leading to absolute deficiency of 
insulin (ADA, 2004). This type occurs at any age but mostly begins in childhood or 
young adulthood. It is treated by insulin, diet and exercise. Type 1 accounts only 5-
10% of patients with diabetes (WHO, 1999). 
Diabetes mellitus Type 2 accounts for 90-95% of diabetes cases. It occurs due to 
insufficient production of insulin by the body or inadequate response to insulin by 
the body tissues (insulin resistance) or both (Engelgau and Geiss, 2000). This type is 
a serious condition that must be managed to avoid the onset and development of 
macrovascular and microvascular complications. It is treated by oral antidiabetic 
agents, insulin in some cases, changing lifestyles, diet and exercise (Koda-Kimble et 
al., 2005).  
Diabetes mellitus is associated with an increase in the risk of developing 
cardiovascular disease (CVD), which is the primary cause of death in individuals 
with both types of diabetes (Kannel and Mcgee, 1979; Morrish et al., 2001; 
Kalofoutis et al., 2007; Paterson et al., 2007). Diabetes type 2 is characterised by the 
presence of insulin resistance that frequently co-exists with multiple cardiovascular 
risk factors such as obesity, hypertension and dyslipidemia (Laaksonen et al., 2002; 
Kendall et al., 2003; Farmer, 2008). Glycemia may be associated with CVD (Hsueh 
et al., 2004), but it co-exists more with microvascular complications, while lipid 
abnormalities that occur in diabetic type 2 subjects are more associated with 
macrovascular complications (Haffner, 1999).  
 3 
Diabetes causes disorders in all metabolic functions of the body; lipid disorder is one 
of such abnormalities, and it is known as the diabetic dyslipidemia (Knopp et al., 
2003). 
 
1.2 Diabetic Dyslipidemia 
Diabetic dyslipidemia is referred to the lipid abnormalities associated with diabetes 
mellitus (Solano and Goldberg, 2006). It is common in the diabetic population and is 
a serious risk factor for coronary heart disease (Syvanne and Taskinen, 1997). 
Diabetic dyslipidemia is characterised by an increase in triglyceride cholesterol 
levels (TG), low levels of high-density lipoproteins (HDL), small, dense low-density 
lipoprotein particles (LDL) with slight increase or normal total cholesterol (TC) 
levels (Wilson et al., 1985; Haffner, 1998; Brunzell and Ayyobi, 2003). The levels of 
LDL in diabetic type 2 patients are generally comparable to those found in the non-
diabetic subjects. However, those small and dense LDL particles are highly 
atherogenic due to their increased susceptibility to oxidation and uptake by the 
arterial wall (Demacker et al., 2000). 
Lipid abnormalities will lead to the development of atherosclerosis (Farmer, 2008), 
the central pathological mechanism that causes the macrovascular complications in 
type 2 diabetes (Fowler, 2008). This will result in 2-4 folds increase in the 
probability of developing vascular complications in diabetes (Stamler et al., 1998). 
Approximately, 75% of all atherosclerotic-related events are mostly due to coronary 
artery disease, while 25% of such events are peripheral or cerebrovascular disease 
(Haffner et al., 1998; Farmer, 2008). Dyslipidemia is a modifiable well-recognised 
risk factor that if identified and treated early may lead to the reduction of both 
incidence and development of CVD (Solano and Goldberg, 2006). 
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1.3 Prevalence of Diabetes Mellitus Type 2 and CVD 
The number of diabetic subjects is becoming larger worldwide. Factors such as age, 
population growth, urbanization and increased prevalence of obesity and physical 
inactivity resulting from an unhealthy diet and sedentary lifestyle contribute to this 
increase (Zimmet et al., 2001; Wild et al., 2004).  
According to the WHO, prevalence of diabetes worldwide in the year of 2000 was 
approximately 171 million in adults 20 years old and above and will be 366 million 
in the year of 2030 (WHO, 2008).  
The International Diabetes Federation (IDF) estimated that over 150 million people 
in the year 2000 were diabetics, this number increased to 194 million people in 2003. 
In the year of 2007 the number was 246 million and expected to reach 380 million in 
the year 2025 (IDF, 2008). This difference in the statistics between WHO and IDF is 
due to the difference in the methodologies and the inclusion criteria used by the IDF 
and that of WHO to estimate diabetes prevalence for subjects 20-79 years old (Wild 
et al., 2004).  
In the United States of America 23.5 million (10.7%) of people 20 years or older 
have type 2 diabetes, 12 million (11.2%) are males and 11.5 million (10.2%) are 
females, while 12.2 million (23.1%) are 60 years or older (ADA, 2007b). North 
American region has the highest prevalence rate of diabetes which is 9.2%, followed 
by the European region with a prevalence of 8.4%. The highest number of people 
with diabetes are found in the Western Pacific region (67 million) followed by the 
European region (53 million) people (IDF, 2008).  
Some ethnic groups appear to be more susceptible for developing diabetes, such as 
Amerindians, African-Americans, Australian aborigines, Hispanics, Pacific Island 
people and South Asians (IDF, 2001). In Malaysia, the National Health and 
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Morbidity Survey I, estimated that the prevalence of diabetes in the year 1960 was 
0.65%, which later increased to 6.3% in 1985, while in the second survey conducted 
in 1996 the prevalence was 8.3%. Studies conducted in the country in 1998 showed 
that between 600,000 and 700,000 people of 30 years and above were diabetics (Lim 
et al., 2000; Omar et al., 2002).  
According to WHO, Malaysia had 942,000 people with diabetes in the year of 2000. 
This number is expected to reach 2,479,000 in 2030 (WHO, 2007). In 2005, an 
estimated 1.1 million people died from diabetes worldwide, approximately 80% of 
them were from the low and middle–income countries, half of the death cases 
occurred among people under the age of 70 and 55% of the cases were women 
(WHO, 2006a).  
In Malaysia, according to the Ministry of Health records, admission to Governmental 
hospitals due to diabetes mellitus increased from 19,629 cases in 1991 to 30,661 
cases in 2001. An increase of 50% in death cases due to diabetes mellitus was 
recorded between the years 1991-2001(Ooyub et al., 2004).  
Ninety-seven percent of adults with diabetes have one or more lipid abnormalities 
(diabetic dyslipidemia). Dyslipidemia is associated with cardiovascular and coronary 
artery diseases that are the primary cause of death among diabetes type 2 patients 
(Fagot-Campagna et al., 2000; Henry, 2001).  
In Malaysia, the prevalence of dyslipidemia among diabetes type 2 subjects is 63-
76% (Mustaffa, 2004).  
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1.4 Diagnosis and Screening of DM Type 2 and Diabetic 
Dyslipidemia 
Screening of DM aims to identify people who are asymptomatic and likely to have 
diabetes; this is done either by detecting all diabetic people in a population or detects 
diabetes among people most likely to have it (WHO, 2002). According to Leahy 
(2000) and Misbin (1999) the following are people who may develop diabetes:  
a) Those who have typical diabetes symptoms.  
b) Have family history. 
c) High risk ethnic group. 
d) Obese or overweight.  
e) Hypertensive people. 
f) Have high TG and cholesterol levels.  
g) Had gestational diabetes or delivered a baby weighing more than 4.5 kg. 
h) Who had Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose 
(IFG). 
Before 1997 there were no standard diagnostic criteria for the diagnosis of diabetes. 
In 1980 WHO, in association with the National Diabetes Data Group (NDDG) in the 
United States developed the criteria for the diagnosis of DM (Miller and Kraemer, 
2000; The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus, 2003). These diagnostic criteria are: 
a) Random plasma glucose (RPG): this test is done during the day regardless of the 
last meal taken. When typical symptoms of diabetes are present, which are polyuria, 
polydipsia and weight loss, RPG ≥ 11.1 mmol/l (200 mg/dl) confirms the diagnosis. 
b) Fasting plasma glucose (FPG): this test is done after at least 8 hours of last meal 
taken and the value ≥ 7 mmol/l (126 mg/dl) confirms diabetes. 
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c) Oral glucose tolerance test (OGTT): this test is done 2 hours after ingestion of a 
glucose load of 75 g dissolved in water and a value of ≥ 11.1 mmol/l (200 mg/dl) 
confirms diabetes (ADA, 2004). OGTT test is not recommended for routine clinical 
use because it is more difficult and more expensive than the other tests (Leahy, 
2000). 
Measurements of HbA1c are useful during therapeutic monitoring but not as a 
diagnostic test because of the poor standardisation among clinical labs (Miller and 
Kraemer, 2000). Diagnostic tests for diabetes are recommended to be done for all 
people 45 years old or above and repeated every 3 years. However, for those at high 
risk the tests must be done more frequently and at younger age (Leahy, 2000). 
In asymptomatic people, diagnosis should not be made depending on one abnormal 
glucose level value but after repeated tests, unless the subject has obvious 
hyperglycemia along with its symptoms (WHO, 2006b). 
For measuring lipid levels, TC and HDL can be measured in fasting and non-fasting 
conditions. For TG the measurements are done after 10-12 hours fasting. LDL values 
are measured using the FriedeWald equation: LDL (mmol/l) = TC-HDL-TG/2.2 
(MOH-Malaysia, 2003). This equation is not valid if TG levels are above 4.5 mmol/l, 
because the ratio of VLDL to serum TG gradually changes with increased TG levels 
leading to a gradual increase in the error of estimated LDL (Nader et al., 1992).  
Lipid targets recommended for diabetic patients are TG ≤ 1.7 mmol/l, HDL ≥ 1.1 
mmol/l and LDL ≤ 2.6 mmol/l. Abnormal values are considered as diabetes 
dyslipidemia (MOH-Malaysia, 2004). 
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1.5 Pathogenesis of Type 2 DM and Diabetic Dyslipidemia 
The specific etiology of type 2 diabetes is not known, but unlike type 1, there is no 
autoimmune destruction of β-cells (ADA, 2004).  
Diabetes mellitus type 2 is characterised by impairment in the function of pancreatic 
β-cells which lead to impairment in insulin secretion, insulin resistance, decrease in 
insulin-mediated glucose transport in muscles and adipose tissue and increase in the 
production of glucose by the liver (Olefsky, 1989; Reaven, 1995; Mahler and Alder, 
1999; Goldstein and Muller-Wieland, 2003).  
The cause of diabetes type 2 may be due to genetic defects that run through patients 
with family history and to this date only little information is known about the genetic 
defects (Leahy, 2000; Cnop et al., 2007).  
Most of the patients in this type are obese, and obesity itself causes a degree of 
insulin resistance (ADA, 2004; Alan et al., 2005). Environmental factors other than 
obesity such as aging, unhealthy diet, physical inactivity, hypertension, lipid 
abnormalities, steroids and pregnancy are all related to insulin resistance and may 
increase the incidence of type 2 diabetes in the third world population (Miller and 
Kraemer, 2000; Lorenzo et al., 2003). Other factors including utilization of specific 
drugs, poor nutrition, hypokalemia and hypocalcemia are also associated with 
increased incidence of diabetes type 2 (Leahy, 2000).  
After glucose ingestion, its homeostasis is maintained by 3 coordinated processes: 
insulin secretion, stimulation of glucose uptake by visceral and peripheral tissues in 
response to hyperinsulinemia and hyperglycemia and suppression of glucose 
production by the liver (Defronzo, 1999). In type 2 diabetes when there is a defect in 
β-cell function and insulin resistance, hepatic glucose production will increase and 
hyperglycemia will develop (Hother-Nielsen and Beck-Nielsen, 1991; Davidson and 
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Peters, 1997). Insulin resistance will lead to increased demands and exhaustion of β-
cells, as a result of circulating insulin levels that will increase potential defects in the 
ability to regulate circulating glucose and lipoproteins (Defronzo et al., 1992). 
Diabetic patients are more susceptible to coronary heart disease (CHD) at younger 
age than non-diabetic individuals, which is the reason of death among the diabetic 
population (Gotto, 2002). Hyperglycemia is known to be a risk factor for 
microvascular complications of the eyes, kidney and nerves, and it is shown to be a 
CVD risk factor (Laakso and Lehto, 1997; Betteridge, 2004).  
According to the United Kingdom Prospective Diabetes Study (UKPDS 35) and 
other studies, the management of hyperglycemia was only associated with reduction 
in microvascular complications and only 16% reduction in the macrovascular 
complications. Macrovascular events were improved by controlling lipid and blood 
pressure abnormalities (Stratton et al., 2000; Stettler et al., 2006; Kelly et al., 2009).  
The mechanism underlying atherosclerosis in type 2 diabetes includes the association 
of several CVD risk factors other than hyperglycemia. These factors are 
dyslipidemia, hypertension, insulin resistance, hemostatic abnormalities, protein 
glycosylation and oxidative stress (Bierman and George, 1992; Betteridge, 2004).  
Increase circulating free fatty acids (FFA) levels is a common abnormality seen in 
insulin resistance as a consequence of increased lipolysis in the adipocytes due to 
poor insulinization (Lewis et al., 1995; Goldberg., 2001). The circulating FFA will 
be taken up by the liver to provide the metabolic substrate for synthesizing the 
endogenous TG-rich VLDL (Grundy, 2006; Farmer, 2008). Insulin resistance will 
cause a reduction in lipoprotein lipase enzyme hydrolytic activity leading to 
increased hepatic production of VLDL with subsequent increase in TG levels 
(Betteridge, 2004). The impaired catabolism and clearance of VLDL are associated 
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with decrease in the transfer of cholesterol into HDL, subsequently a reduction in 
this cardioprotective lipoprotein will arise (Superko, 2000; Farmer, 2008). Low HDL 
and high TG levels are associated with abnormal small, dense LDL particles which 
are highly atherogenic (Papadakis et al., 2001; Fonseca, 2003).  
The high atherogenicity of these LDL particles resulted from its increased 
susceptibility to oxidation, endothelial cytotoxicity and increased ability to cross the 
endothelial barrier (Farmer, 2008). Moreover, in diabetic subjects, LDL is less 
efficiently bound to its receptor due to an increase in the rate of glycation of 
apolipoprotein B, thus the clearance of LDL from plasma is delayed, as a result LDL 
uptake will increase by macrophages leading to the formation of a foam cell (Lyons, 
1992). 
High TG levels are associated with the accumulation of the atherogenic remnant 
particles and with the low HDL levels (Farmer, 2008). Thus the diabetic 
dyslipidemia is characterised by high TG levels, low HDL levels and small, dense 
LDL particles (Solano and Goldberg, 2006).  
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1.6 Management of DM Type 2 and Diabetic Dyslipidemia 
The initial management for patients with type 2 diabetes requires a programme that 
combines diet, exercise, smoking cessation and the use of oral antidiabetic agents 
and/or insulin together with antidyslipidemic medication (Miller and Kraemer, 2000; 
Kalofoutis et al., 2007).  
The treatment programme includes: education about diabetes, nutritional 
recommendations and planning, exercise, use of oral antidiabetic agents and/or 
insulin and managing the associated conditions and complications. These factors 
require the cooperation of a health team including the diabetologist, the nutritionist 
and the diabetes educator. If complications developed, it is important that sub-
specialists, such as neurologist, nephrologist, cardiologist and ophthalmologist be 
involved (WHO, 2006b).  
 
1.7 Diet Composition for Diabetic Dyslipidemic Patients 
1.7.1 Carbohydrates  
There is strong evidence that the total amount of carbohydrates consumed in a meal 
is more important than the source of it. Accordingly, sucrose and sucrose containing 
food does not need to be restricted for diabetic patients but substituted for other 
carbohydrates (WHO, 2006b). Diets containing carbohydrates from vegetables, 
fruits, legumes, grains and low-fat milk are good for health and encouraged to be 
consumed by diabetics (ADA, 2007a). There are evidences suggesting that 
consuming high–fiber diets (150 g/day) by the diabetic patients have a good effect on 
glycemia, hyperinsulinemia and lipidemia (WHO, 2006b). 
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1.7.2 Fat  
The goal from reducing the intake of dietary fat by diabetic patients is to minimize 
the risk of developing CVD. Saturated and trans saturated fatty acids are the main 
source of LDL cholesterol, thus saturated fat must be limited to less than 7% of total 
calories. Trans fat intake must be minimized and dietary cholesterol be limited to 200 
mg/day (Garg et al., 1994; Wood et al., 1998; ADA, 2007a). Diets low in saturated 
FA and high in carbohydrates or monounsaturated FA will decrease the LDL but 
may also decrease HDL levels; poly- and mono-unsaturated FA diet will reduce both 
total plasma cholesterol and LDL levels (WHO, 2006b). The consumption of 2g/day 
of plant sterol and stanol esters was shown to decrease total plasma TC and LDL 
levels as they block intestinal and dietary cholesterol absorption (ADA, 2007a). 
 
1.7.3 Proteins  
In diabetic subjects 10-20% of total energy intake may be provided from proteins and 
only few studies suggest the modification of this intake. Protein ingestion has no 
effect on increasing glucose levels, but it stimulates insulin secretion in patients with 
controlled DM. Only limited studies suggest that it may be good to limit protein daily 
intake to not more than 20% to avoid the development of nephropathy (Goldstein and 
Muller-Wieland, 2003; Franz et al., 2004). 
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1.7.4 Vitamins and minerals  
If diabetes is not controlled it may be associated mostly with deficiency in vitamins 
and minerals. Patients must be made to know the importance of getting adequate 
amount of these nutrients from healthy diet. However, routine supplement with 
antioxidants like vitamins E and C and carotene is not recommended, due to lack of 
evidence on their efficacy and long-term safety. Deficiency in chromium, 
magnesium, potassium and possibly zinc may aggravate carbohydrate intolerance, 
but they are not recommended supplementations since benefits from such 
supplementations have not been demonstrated (ADA, 2007a). 
 
1.8 Exercise  
Exercise is important to improve diabetic control and decrease the risk of CVD; it 
also has a good effect on dyslipidemia by raising HDL levels significantly and 
lowers cholesterol and TG levels. Exercise is good for weight control because it 
burns calories and helps in reducing tension and stress. Furthermore, regular exercise 
enhances body response to insulin and may make pharmacological therapy more 
effective. Thus, it is good for the diabetic patients to do sports, unless there are 
complications that prevent it. Physical examination should be conducted by a 
physician before starting on an exercise programme (ADA, 2001; WHO, 2006b). 
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1.9 Therapeutic Management of Type 2 DM and Dyslipidemia 
If 3-6 months period of diet and exercise therapy failed to control glucose and lipid 
elevated levels, then pharmacological therapy should be started (Miller and Kraemer, 
2000). According to the UKPDS, controlling glycemia will reduce the progression 
and onset of microvascular complications, while controlling blood pressure and 
abnormal lipid levels will reduce the development of macrovascular complications in 
type 2 diabetic patients (Koda-Kimble et al., 2005). Thus, the use of lipid lowering 
medications particularly statins as a first-line therapy is recommended to prevent or 
decrease the incidence of CVD (National Cholesterol Education Program NCEP, 
2002). Some oral antidiabetic agents have effects on lipid levels such as lowering TG 
and LDL levels with slight or no effect on rising HDL (Henry, 2001). Different 
classes of oral antidiabetic agents are available in addition to insulin for the treatment 
of diabetes type 2 patients (BNF, 2005). 
 
1.9.1 Insulin  
Insulin is used when treatment with oral antidiabetic agents alone failed to control 
glucose levels in some type 2 diabetic patients who had diabetes for many years. It is 
used either combined to oral antidiabetic agents or as monotherapy in cases where 
oral antidiabetics must be discontinued (Miller and Kraemer, 2000). Insulin in some 
studies showed some effect on reducing serum cholesterol and TG levels, but with no 
effect on HDL. However, other studies showed that there was an increase in HDL 
levels (Merrin and Elkeles, 1991). 
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1.9.2 Oral antidiabetic agents  
1.9.2.1 Sulfonylureas  
Two generations are available in this class; the first generation sulphonylureas 
include acetohexamide, chlorpropamide, tolazamide and tolbutamide, while those of 
the second generation include glibenclamide, glimepiride and glipizide. 
Agents of this group act by stimulating the secretion of insulin from the pancreatic β-
cells and enhancing its sensitivity to glucose (Miller and Kraemer, 2000). These 
agents are equally effective in their glucose lowering effect but differ in their 
pharmacokinetics and side effects properties (Zimmerman, 1997; Koda-Kimble et 
al., 2005). Sulfonylureas may have a slight role in correcting serum lipids. Some 
studies found that chlorpropamide caused a reduction in both TG and VLDL 
lipoprotein with a rise in HDL levels. Glipizide, in another study, was found to 
reduce TG levels with no effect on HDL (Merrin and Elkeles, 1991). Agents of this 
group are safe but may cause hypoglycemia and weight gain, and they are also 
effective when used as monotherapy or combined with other oral antidiabetics or 
insulin (Miller and Kraemer, 2000).  
 
1.9.2.2 α-Glucosidase inhibitors  
Acarbose and miglitol are the only two agents available in this class of oral 
antidiabetics. These agents slow the digestion of complex carbohydrates by 
reversibly inhibiting glucosidases enzymes in the small intestine, as a result glucose 
absorption will be delayed and postprandial glucose levels will decrease (Yee and 
Fong, 1996; Koda-Kimble et al., 2005). They are effective as monotherapy or when 
combined with other oral antidiabetics or insulin. These agents have no effect on 
serum lipids (Miller and Kraemer, 2000). 
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1.9.2.3 Nonsulfonylurea insulin secretagogues  
Drugs in this class include repaglinide and nateglinide. Nonsulfonylureas acts by 
closing adenosine triphosphate (ATP) potassium channels in the β-cells. This 
blockade will cause depolarization of the membrane and opening of the calcium 
channels. The resulting increase in calcium influx will stimulate insulin secretion 
(Koda-Kimble et al., 2005). These agents are effective when used as monotherapy or 
in combination with metformin or thiazolidinediones. Since these agents have the 
same action as sulfonylureas hence no beneficial effect is added when they are used 
together (Miller and Kraemer, 2000). 
 
1.9.2.4 Thiazolidinediones  
Agents under this class are insulin sensitizers acting by reducing resistance to insulin 
in liver and muscles, thus stimulating glucose utilization and reducing its output by 
the liver (Mudaliar and Henry, 2001; Koda-Kimble et al., 2005). Rosiglitazone and 
pioglitazone are the two agents available in this class, and they are effective as 
monotherapy or in combination with other oral antidiabetics or insulin (Miller and 
Kraemer, 2000). According to one study, these agents are shown to have beneficial 
effect on serum lipids by decreasing TG levels and increasing HDL by 19% (Henry, 
2001). 
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1.9.2.5 Biguanides  
Metformin is the only member available in this class (BNF, 2005). It is of intrest in 
this research because of its wide usage in Hospital Pulau Pinang outpatient clinic and 
its effect on lipids in diabetic type 2 dyslipidemic patients. 
 
1.9.2.5.1 History  
The parent compound of this class is guanidine. It was derived from the plant French 
lilac (Galega officinalis) and has been used in eastern and southern Europe early in 
the 20th century. Guanidine was shown to have hypoglycemic properties, but it was 
very toxic to be given to humans. In the late of 1950s phenformin 
(phenethylbiguanide) and metformin (dimethylbiguanide) were developed (Miller 
and Kraemer, 2000).  
Phenformin was the first biguanide available in the United States until 1977, when it 
was withdrawn from the market due to its high association with increasing incidence 
of fatal lactic acidosis. Metformin was available in the United States only in 1995, 
whereas the generic version came out in 2002 (Klepser and Kelly, 1997; Koda-
Kimble et al., 2005).  
Metformin is a crystalline compound, white in color, freely soluble in water and 
insoluble in chloroform, aceton and ether; its molecular formula is C4H11N5.HCL with 
a molecular weight of 165.63. Metformin (N, N-dimethylimidodicarbonimidic 
diamide hydrochloride) has the following chemical structure shown in Figure 1 
(Bristol-Myers Squibb, 2008): 
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Figure 1: Metformin hydrochloride chemical structure (Prescribing information 
leaflet for Glucophage®, Bristol-Myers Squibb Company, 2008). 
 
 
1.9.2.5.2 Mechanism of action  
Metformin HCL acts as an oral antidiabetic agent by: 
a) Decreasing gluconeogenesis and hepatic glucose production (Hundal et al., 2000). 
b) Improving peripheral sensitivity to insulin by increasing utilization and uptake of 
glucose by the peripheral tissues (Kimmel and Inzucchi, 2005). 
c) Reducing free fatty acid concentration and oxidation that may be related to its 
ability to decrease hepatic glucose production and increasing insulin-mediated 
glucose disposal in the muscle (Miller and Kraemer, 2000). 
Metformin has a desirable effect on lipids by decreasing TC and TG with small or no 
change on HDL was observed (Kirpichnikov et al., 2002; Koda-Kimble et al., 2005). 
Some studies showed that metformin could reduce blood pressure in case of 
hypertension. Furthermore, it may decrease atherosclerosis processes (Tandon, 
2007). 
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1.9.2.5.3 Pharmacokinetics  
When taken orally the bioavailability of metformin is 50-60%. The presence of food 
causes a slight delay in its absorption, which will reduce the bioavailability. It is not 
bounded to plasma proteins and its steady state concentration in plasma is reached 
within 24-48 hours (Bristol-Myers Squibb, 2008). 
Metformin is excreted unchanged in urine and does not undergo hepatic metabolism 
or biliary excretion (Bailey and Turner, 1996). This clearance is 3-4 times greater 
than creatinine clearance, indicating that the drug is eliminated by renal tubular 
secretion, almost 90% of the drug is eliminated renally after absorption within 24 
hours (Scheen, 1996; Miller and Kraemer, 2000). Metformin plasma half life is 6.2 
hours, while its blood half life is 17.6 hours, which indicates its distribution into the 
red blood cells (Bristol-Myers Squibb, 2008). 
 
1.9.2.5.4 Adverse effects  
Gastrointestinal transient side effects may occur during metformin usage such as 
abdominal discomfort, diarrhea, nausea, vomiting, flatulence, metallic taste, and 
anorexia. These side effects can be overcome by taking the drug with meals or 
starting with a low dose and increasing it gradually. Headache, rash and skin 
reactions may develop in some cases. Occasionally, the concentration of vitamin B12 
may decrease but developing anemia is rare (BNF, 2005).  
Lactic acidosis is the most serious side effect that may develop during metformin 
usage and can lead to death, but it is very rare with an incidence of 0.03 cases/1000 
patients-year. However, if developed it may be fatal in 50% of cases (Miller and 
Kraemer, 2000; Salpeter et al., 2003). Lactic acidosis symptoms are weakness, 
abdominal distress, malaise, myalgia and heavy strained breathing. It is characterised 
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by elevated blood lactate levels > 5mmol/l, increased lactate/pyruvate ratio, 
decreased pH of the blood and electrolyte disturbance with an increased anion gap. 
Metformin plasma concentration is found to be > 5µg/ml (Bristol-Myers Squibb, 
2008).  
Metformin is rarely associated with lactic acidosis because it is not metabolised and 
does not inhibit glucose peripheral oxidation or enhance peripheral production of 
lactate. It may increase lactate production in the liver and gut as it may decrease the 
conversion of glucose lactate to glucose (Koda-Kimble et al., 2005). Metformin does 
not cause hypoglycemia and is associated with weight loss more than weight gain 
(Miller and Kraemer, 2000). 
 
1.9.2.5.5 Precautions and contraindications  
Metformin is contraindicated in cases of renal impairment or renal disease (when 
creatinine ≥ 1.5 mg/dl), liver disease, cardiac heart failure, shock, myocardial 
infarction or sepsis as these conditions may increase the risk of lactic acidosis (Koda-
Kimble et al., 2005). It is also contraindicated in acute or chronic metabolic acidosis 
such as diabetic ketoacidosis with or without coma or in case of hypersensitivity to 
metformin (Bristol-Myers Squibb, 2008).  
Metformin should be used with caution in elderly patients because advanced age is 
associated with reduction in renal function. All elderly patients especially those 
above 80 years old should receive minimum effective doses with regular monitoring 
of renal function (Koda-Kimble et al., 2005). The drug must be temporarily 
discontinued in patients undergoing radiological procedures where intravenous 
iodinated contrast materials are used or surgery as these conditions may cause 
changes in renal status (Miller and Kraemer, 2000). 
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1.9.2.5.6 Metformin-drug interactions  
Careful monitoring and dose adjustment is recommended on coadministration of 
metformin with furosemide as it will increase plasma and blood concentration of 
metformin but with no significant change in its renal clearance. 
 Nifedipine when used concomitantly with metformin will increase the plasma 
concentration and urinary excretion of metformin and also shown to enhance 
metformin absorption (Bristol-Myers Squibb, 2008).  
Cimetidine when administered together with metformin will also increase plasma 
and blood concentration of metformin and competes with it for the renal tubular 
transport system. Such interactions are also seen when metformin is administered 
with cationic drugs like ranitidine, amiloride, digoxin, morphine, procainamide, 
quinidine, quinine, triamterene, trimethoprim or vancomycin (BNF, 2005).  
Drugs like thiazides or other diuretics, corticosteroids, calcium channel blockers, 
phenytoin, oral contraceptives, estrogens, thyroid products, phenothiazines, nicotinic 
acid, isoniazid and sympathomimetics seem to cause hyperglymia and loss of 
glycemic control so patients must be monitored for loss of blood glucose control 
(Bristol-Myers Squibb, 2008).  
Hypoglycemia is not developed during metformin monotherapy but may occur when 
it is used in combination with insulin or sulfonylurea (Miller and Kraemer, 2000). 
Patients should be warned about excessive intake of alcohol as it may enhance the 
effect of metformin on lactate metabolism (Koda-Kimble et al., 2005). 
Metformin usage is not recommended during pregnancy and for patients under 10 
years old (Bristol-Myers Squibb, 2008). 
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1.9.2.5.7 Dosage and administration  
The dose of metformin must be divided according to effectiveness and tolerance. The 
minimum effective dose is 500 mg to be taken 2-3 times in a day not exceeding the 
maximum daily dose which is 2250 mg or 850 mg once daily to be given with meals 
to decrease gastrointestinal adverse effects (BNF, 2005). Metformin should be 
started with a low dose, then increasing it gradually not only to overcome the 
gastrointestinal adverse effects, but also to help in identifying the minimum effective 
dose for adequate blood glucose control (Miller and Kraemer, 2000).  
The therapeutic goal for the treatment with metformin is to reduce FPG and HbA1c to 
normal or around normal values by using the lowest effective dose, thus the FPG 
should be monitored to identify this dose. HbA1c monitoring is also required as three 
months’ interval (Bristol-Myers Squibb, 2008). 
 
1.9.3 Antidyslipidemic agents  
Atherosclerosis is the main pathological process that leads to the development of 
macrovascular complications in diabetes type 2 patients (Boyle, 2007). Treating type 
2 diabetes should focus on managing CVD risk factors including hypertension and 
dyslipidemia as well as controlling elevated glucose levels to reduce microvascular 
complications (Betteridge, 2004).  
Diabetic dyslipidemia is a combined hyperlipidemia with high TG, low HDL and 
small, dense LDL particles which requires the combination of antidyslipidemic drugs 
together with oral antidiabetics to normalize glucose and lipid levels when the diet 
and exercise alone fail to control both (Knopp et al., 2003). Classes of 
antidyslipidemics are: 
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1.9.3.1 Bile acid sequestrants  
Cholestyramine and colestipol are the two agents of this class. They act by binding 
bile acids and preventing their reabsorption which will enhance hepatic conversion of 
cholesterol to bile acids causing rise in LDL receptors and increase its clearance 
(Einarsson et al., 1991; BNF, 2005).  
These agents decrease LDL levels by 15-30% and increase HDL by 3-5% but may 
increase TG levels, thus they must be used with caution. They are usually used in 
combination with statins as a second–line therapy or sometimes as first-line in 
patients who cannot tolerate or allergic to statins (WHO, 2006b). 
 
1.9.3.2 Ezetimibe  
This agent inhibits cholesterol absorption from the intestine; it lowers LDL levels 
and is used in combination with statins (BNF, 2005). This agent has no effect on TG, 
but it decreases LDL levels by 15-20% and increase HDL levels by 3-4% (Bays et 
al., 2001; WHO, 2006b).  
 
1.9.3.3 Nicotinic acid  
Its main action is to decrease hepatic production of VLDL by decreasing TG 
production (Kraemer and Miller, 2000). Nicotinic acid reduces LDL levels by 15-
25% and decrease TG levels by 20-50% and increases HDL levels 15-35% (Grundy 
et al., 1981; WHO, 2006b). It is used in combination with statins or alone in patients 
who have sensitivity to statins (BNF, 2005). Because of its mild action on raising 
blood glucose, nicotinic acid should be used with caution in diabetic patients and it is 
better to keep the dose below 2 g/day. It should be avoided in patients with poor 
glycemic control (Solano and Goldberg, 2006). 
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1.9.3.4 Fibrates  
Bezafibrate, ciprofibrate, fenofibrate and gemfibrozil are agents of this class. They 
act by enhancing lipoprotein lipase activity leading to increase VLDL catabolism and 
subsequent reduction in VLDL and TG concentrations (Kraemer and Miller, 2000). 
The effect of fibrates on LDL is variable (BNF, 2005), in patients with elevated TG 
levels fibrates may increase LDL levels. When TG levels are normal these agents 
will reduce LDL levels by 5-20%, reduce TG levels by 20-50% and rise HDL levels 
by10-20% (WHO, 2006b). Fibrates may reduce the risk of CVD in patients with 
elevated TG levels either alone or in combination with statins. Combination with a 
statin will increase the risk of myopathy and in this case high statin doses must be 
avoided (Prueksaritanont et al., 2002; Solano and Goldberg, 2006). 
 
1.9.3.5 Statins or HMGCoA reductase inhibitors  
Atrovastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin are the 
agents of this class. They have the most potent efficacy in lowering cholesterol 
(BNF, 2005). These agents decrease LDL levels by 20-40% with initial doses and 
35-60% with maximum doses; decrease TG levels by 15-45% and rises HDL levels 
by 5-8% (Jones et al., 1998). All statins have the same mechanism of action which is 
the inhibition of the enzyme that is involved in cholesterol synthesis 3-hydroxy-3-
methylglutaryl coenzyme A reductase, particularly in the liver (Mckenney, 2005). 
This research will focus on lovastatin because it is the drug most prescribed for 
patients with diabetic dyslipidemia in Hospital Pulau Pinang. 
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1.9.3.5.1 History of Lovastatin  
 During 1970s several metabolites were isolated from Penicillium citrinum. They 
could inhibit HMGCoA reductase enzyme which is the rate-limiting step in 
cholesterol synthesis. One of these metabolites was the compactin, but it was never 
released to the market for an unknown reason (Kraemer and Miller, 2000). Shortly 
after that a related compound was isolated from Aspergillus terreus and from the 
fungi Pleurotus ostreatus, which is mevinolin or lovastatin (Bobek et al., 1998). It 
was approved for sale in the United States in 1987 (Kraemer and Miller, 2000). 
Lovastatin is a nonhygroscopic white crystalline powder, insoluble in water and 
sparingly soluble in methanol, ethanol and acetonitrile; its molecular formula is 
C24H36O5 with a molecular weight of 404.55. Chemical structure of lovastatin is 
shown in Figure 2 (Merck and Co., 2008). 
 
 
Figure 2: Lovastatin chemical structure (Prescribing information leaflet for 
Mevacor®, Merck and Co. Inc., 2008). 
 
 
 
 
